Search Bar & Filters
Found 7 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating the effectiveness of Vagus Nerve Stimulation VNS Therapy as an additional treatment for people with treatment-resistant depression. The study compares active VNS treatment with a no stimulation control over a 12-month period to see if VNS can reduce depressive symptoms measured by several depression scales. This is a prospective, multi-center, randomized, controlled, and blinded trial involving subjects who have VNS devices implanted. Participants receive the VNS implant, and after at least two weeks, they are randomized to either have the device activated or not activated for the first 12 months. Those in the control group can receive stimulation after 12 months. After the initial 12-month randomized phase, all participants transition into an open-label, long-term study lasting about 5 years. New subjects may also enroll directly into this extension phase. During the trial, participants are assessed regularly using multiple depression rating scales and questionnaires to monitor changes in symptoms, response times, remission, and adverse events. Safety and quality of life measures are also tracked. The study includes thorough monitoring of depressive symptoms and overall functioning for up to 12 months post-randomization, followed by long-term observation for several years.
Actively Recruiting
Healthy Volunteer
Researchers are evaluating the real-world impact, including safety and test accuracy, of the Galleri4 multi-cancer early detection blood test in Medicare beneficiaries aged 50 years and older. This multi-center prospective cohort study aims to represent the Medicare population and compares usual care with and without the addition of the Galleri test. The study focuses on screening for cancer and assessing how the test affects cancer diagnosis and management over time. Participants are grouped into two arms one receiving the Galleri test alongside usual care, and a second group receiving usual care alone without the Galleri test. The Galleri test involves blood collection and multi-cancer early detection testing with results returned to participants. The study is non-randomized and runs parallel for both groups, observing outcomes over up to three years. During the study, participants are monitored for the incidence of late-stage stage IV cancers. Researchers also track safety by counting invasive procedures prompted by test results, adherence to recommended cancer screenings, and healthcare resources used for cancer diagnostics. The total study duration includes up to three years of follow-up to observe outcomes, with no masking or blinding involved.
Actively Recruiting
Researchers are studying Medicare beneficiaries with Lumbar Spinal Stenosis LSS and Neurogenic Claudication NC to compare outcomes after two different procedures MILD Percutaneous Image-Guided Lumbar Decompression and Interspinous Process Decompression IPD. This observational study tracks patients treated since January 1, 2017, evaluating the rates of surgical and minimally invasive interventions as well as any harms related to these procedures over 24 months. The study uses Medicare claims data and does not require prior patient consent or IRB oversight. The study includes two groups of patients those who received the MILD procedure, involving partial decompression under image guidance by removing tissue and bone at the affected spinal level, and those who underwent IPD, a device-based decompression technique. Both groups are observed through Medicare data for two years after their initial procedure to assess the need for further surgeries or interventions and to monitor for any complications. Participants are followed for 24 months after their index procedure using Medicare claims data. Researchers monitor the rates of harms associated with the initial treatment and the frequency of additional surgical or minimally invasive interventions. Since this is an observational study, data collection relies on existing Medicare records without direct patient involvement, and the study will continue enrolling patients until the sponsor stops it.
Actively Recruiting
Researchers are evaluating the long-term safety and tolerability of zigakibart in adults with primary immunoglobulin A nephropathy IgAN. This open-label extension study includes participants who have completed previous zigakibart trials, aiming to gather extended safety information and assess the drugs effects over time. The study is sponsored by Novartis Pharmaceuticals and continues from earlier phase 12 and phase 3 studies. Participants will receive zigakibart as a solution for subcutaneous injection at a dose of 600 mg every two weeks. This is a single-group, open-label study where all participants receive the active treatment. The study monitors safety and tolerability through various assessments over several years, including serum drug levels and immunoglobulin measurements. Participants are followed for up to approximately five years to observe any adverse events and changes in kidney function. During the study, participants will have scheduled visits for clinical evaluations, laboratory testing, and monitoring of adverse events. Key measurements include urinary protein to creatinine ratio UPCR, estimated glomerular filtration rate eGFR, immunoglobulin levels, and detection of anti-drug antibodies. Safety labs and vital signs will be tracked throughout. The studys main outcomes focus on the number of participants experiencing adverse events, with follow-up continuing 24 weeks after treatment ends. Overall participation may last up to six years, including treatment and post-treatment monitoring.
Actively Recruiting
Researchers are evaluating the pharmacokinetic profile, safety, efficacy, and immunogenicity of HLX13, an ipilimumab biosimilar, compared to the US-sourced YERVOY in adults with unresectable hepatocellular carcinoma HCC who have not previously received systemic therapy. This phase I, multicenter, randomized, double-blind study aims to understand how these treatments behave in the body and their effects on this advanced liver cancer. Participants will be randomly assigned to receive either HLX13 or US-sourced YERVOY at a dose of 3 mgkg on the first day of each 3-week cycle, for up to four cycles. Additionally, all subjects will receive EU-sourced OPDIVO nivolumab at 1 mgkg on the first day of each 3-week cycle for four cycles. Those who benefit from OPDIVO treatment may continue with local-sourced OPDIVO every 4 weeks for up to two years after randomization. During the study, participants will undergo blood tests to measure drug concentrations and immune response at multiple points up to 20 weeks after the first dose. Safety will be closely monitored through physical exams, vital signs, laboratory tests, and heart monitoring for up to 13 weeks after dosing. Researchers will also assess tumor response and record any adverse events during treatment and a 90-day safety follow-up period. Overall, participants may be involved in the study for several months, with continued treatment and monitoring as appropriate.
Actively Recruiting
Researchers are evaluating whether catheter-based endovascular left atrial appendage occlusion can reduce the risk of ischemic stroke or systemic embolism in people with atrial fibrillation who remain at high stroke risk despite ongoing oral anticoagulation treatment. This multicenter, open-label, randomized controlled trial with blinded assessment aims to clarify the benefit of this intervention for stroke prevention in this population. Participants are randomly assigned to receive either the WATCHMAN device for left atrial appendage occlusion or standard medical care without this procedure. The WATCHMAN device is placed via a catheter to close off the left atrial appendage. Participants continue their oral anticoagulation as prescribed. The study expects an average follow-up of about 4 years, with the primary analysis conducted after 265 stroke or embolism events have occurred. During the study, participants undergo regular monitoring and assessments to track the occurrence of ischemic stroke, systemic embolism, and other cardiovascular events. Cognitive function is also evaluated using the Montreal Cognitive Assessment. Safety and mortality outcomes will be recorded throughout the trial duration. Participants are followed for the full study period estimated at around 4 years to gather comprehensive data on the interventions effects.
Actively Recruiting
This research investigates how stimulating a specific brain region influences craving and opioid use in people with opioid use disorder OUD. The study focuses on applying intermittent theta burst stimulation iTBS, a form of repetitive transcranial magnetic stimulation rTMS, to the left dorsolateral prefrontal cortex L DLPFC. The goal is to examine whether this brain stimulation can reduce craving and opioid use in individuals currently treated with buprenorphine. The study also explores brain changes using optional magnetic resonance imaging MRI. Participants will receive 8 weekly sessions of FDA-approved L DLPFC-targeted iTBS or sham stimulation, with two iTBS sessions per visit separated by 50 minutes. Before treatment, individuals are randomly assigned to active or sham groups, where sham involves flipping the coil to mimic the procedure without actual brain stimulation. Optional MRI scans are offered before the first iTBS session and after completion of the 8-week intervention to assess brain connectivity and activity. Follow-up visits occur at weeks 10, 12, and 20 to monitor outcomes. During the study, participants attend 12 visits over about 5 months, each lasting 1 to 2 hours. They complete interviews, questionnaires about opioid use and psychiatric symptoms, and urine toxicology tests. Optional MRI visits include cognitive tasks and brain imaging. Safety is monitored through medical history assessments and specific screening questionnaires. The main measurements focus on changes in craving using the Opioid Craving Scale and brain connectivity changes via MRI. Participants who initially receive sham stimulation are offered active iTBS after the study concludes.